Whiteside Theresa L, Mandapathil Magis, Szczepanski Miroslaw, Szajnik Marta
University of Pittsburgh, Cancer Institute, PA 15213, USA.
Bull Cancer. 2011 Feb;98(2):E25-31. doi: 10.1684/bdc.2010.1294.
Human tumors utilize many different mechanisms of immunosuppression to prevent immune cells from exercising their antitumor activities. These mechanisms, which enable the tumor to escape from the host immune system and to progress, are being intensively investigated in hope of finding therapeutically safe and effective inhibitors able to counteract tumor-induced immunosuppression. Three of more recently discovered tumor-related suppression mechanisms, i.e. accumulations of adenosine-producing regulatory T-cells (Treg) in the tumor microenvironment, release by tumors of suppressive microvesicles (TMV) and expression of toll-like receptors (TLR) on the tumor cell surface, are described in this review. All contribute in a varying degree to creating a milieu favorable for the tumor and unfavorable for immune effector cells. Tumor escape has been a major problem in cancer immunotherapy and it has been held responsible for the failure of many immune interventions in cancer. For this reason, it is important to study and understand the various suppressive pathways human tumors utilize. Future antitumor immunotherapies are likely to include inhibitors of tumor-induced suppression with the goal of restoring antitumor immune responses in patients with cancer.
人类肿瘤利用多种不同的免疫抑制机制来阻止免疫细胞发挥其抗肿瘤活性。这些使肿瘤能够逃避宿主免疫系统并得以进展的机制正在被深入研究,以期找到治疗上安全有效的抑制剂来对抗肿瘤诱导的免疫抑制。本文综述了最近发现的三种与肿瘤相关的抑制机制,即肿瘤微环境中产生腺苷的调节性T细胞(Treg)的积累、肿瘤释放抑制性微泡(TMV)以及肿瘤细胞表面 toll 样受体(TLR)的表达。所有这些机制都在不同程度上有助于营造一个有利于肿瘤而不利于免疫效应细胞的环境。肿瘤逃逸一直是癌症免疫治疗中的一个主要问题,并且被认为是许多癌症免疫干预失败的原因。因此,研究和了解人类肿瘤利用的各种抑制途径很重要。未来的抗肿瘤免疫疗法可能会包括肿瘤诱导抑制的抑制剂,目标是恢复癌症患者的抗肿瘤免疫反应。